Review top news and interview highlights from the week ending February 2, 2024.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
According to Federal Register notices, the guidance documents are updated versions of drafts originally published in March 2022.
The chief medical advisor of the Muscular Dystrophy Association discussed how directed evolution may help develop AAV capsids better suited for treating neuromuscular diseases.
Kyverna has also announced data on its proprietary CAR-T manufacturing process, Ingenui-T.
The associate professor of clinical ophthalmology at University of Miami discussed the first topical application of gene therapy to the eye.
The multinational, open-label EMERGENE study will seek to enroll 15 patients with LGMD2E/R4 in total.